Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Chinese firm plan to...

    Chinese firm plan to buy Gland Pharma faces CCEA objections

    Written by Ruby Khatun Khatun Published On 2017-08-04T09:14:57+05:30  |  Updated On 4 Aug 2017 9:14 AM IST
    Chinese firm plan to buy Gland Pharma faces CCEA objections

    New Delhi: The CCEA has raised objections to the Rs 8,800 crore proposal of Chinese pharma firm Shanghai Fosun to acquire majority stake in domestic company Gland Pharma, a development that come amid heightened tensions between India and China over border dispute.


    The Cabinet Committee on Economic Affairs (CCEA) in its meeting last month did not approve the proposal, said sources who did not want to be identified.

    The ostensible reason behind holding back the approval is the modern injectable technology that the Hyderabad-based Gland Pharma has, which the government is wary of falling into foreign hands.

    CCEA has raised certain objections over the deal, said another source without specifying the exact reasons.

    In April, the proposal was approved by the then inter- ministerial body foreign investment promotion board (FIPB).

    It had recommended the Rs 8,800 crore foreign investment proposal of Gland Pharma Ltd to the CCEA for approval.

    The Chinese firm sought to acquire stake in Gland Pharma through its subsidiaries outside India, namely Fosun Pharma Industrial Ltd, Fosun Industrial Co Ltd, Ample Up Ltd, Lustrous Star Ltd and Regal Gesture Ltd.

    Subsequently, Fosun would get contractual right to acquire 100 per cent shares of Gland Pharma from other shareholders of the company in one or more tranches, as per the proposal approved by FIPB.

    Proposals over Rs 5,000 crore approved by the then FIPB required CCEA approval.

    The decision on Fosun came amid face-off between the armies of India and China near the Sikkim sector that are inching towards the third month.


    When contacted, Gland Pharma said it was yet to get any communication from the government.

    "We have not had any official communication from any of the governmental departments so far," Gland Pharma Vice Chairman and Managing Director Ravi Penmetsa said.
    acquireAcquisitionCabinet Committee on Economic AffairsCCEAForeign Investment Promotion BoardFosunFosun PharmaceuticalGland PharmaobjectionsRavi Penmetsa
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok